Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04763, South Korea.
GeneMedicine CO., Ltd., Seoul 04763, South Korea.
ACS Nano. 2024 Oct 15;18(41):27869-27890. doi: 10.1021/acsnano.4c02165. Epub 2024 Oct 2.
Systemic delivery of oncolytic adenovirus (oAd) for cancer gene therapy must overcome several limitations such as rapid clearance from the blood, nonspecific accumulation in the liver, and insufficient delivery to the tumor tissues. In the present report, a tumor microenvironment-triggered artificial lipid envelope composed of a pH-responsive sulfamethazine-based polymer (PUSSM)-conjugated phospholipid (DOPE-HZ-PUSSM) and another lipid decorated with epidermal growth factor receptor (EGFR) targeting peptide (GE11) (GE11-DOPE) was utilized to encapsulate replication-incompetent Ad (dAd) or oAd coexpressing short-hairpin RNA (shRNA) against Wnt5 (shWnt5) and decorin (dAd/LP-GE-PS or oAd/LP-GE-PS, respectively). In vitro studies demonstrated that dAd/LP-GE-PS transduced breast cancer cells in a pH-responsive and EGFR-specific manner, showing a higher level of transduction than naked Ad under a mildly acidic pH of 6.0 in EGFR-positive cell lines. In vivo biodistribution analyses revealed that systemic administration of oAd/LP-GE-PS leads to a significantly higher level of intratumoral virion accumulation compared to naked oAd, oAd encapsulated in a liposome without PUSSM or EGFR targeting peptide moiety (oAd/LP), or oAd encapsulated in a liposome with EGFR targeting peptide alone (oAd/LP-GE) in an EGFR overexpressing MDA-MB-468 breast tumor xenograft model, showing that both pH sensitivity and EGFR targeting ability were integral to effective systemic delivery of oAd. Further, systemic administration of all liposomal oAd formulations (oAd/LP, oAd/LP-GE, and oAd/LP-GE-PS) showed significantly attenuated hepatic accumulation of the virus compared to naked oAd. Collectively, our findings demonstrated that pH-sensitive and EGFR-targeted liposomal systemic delivery of oAd can be a promising strategy to address the conventional limitations of oAd to effectively treat EGFR-positive cancer in a safe manner.
用于癌症基因治疗的全身性递送溶瘤腺病毒(oAd)必须克服一些限制,例如从血液中迅速清除、非特异性地在肝脏中积累以及向肿瘤组织的输送不足。在本报告中,利用由 pH 响应性磺胺嘧啶基聚合物(PUSSM)-缀合的磷脂(DOPE-HZ-PUSSM)和另一种用表皮生长因子受体(EGFR)靶向肽(GE11)修饰的脂质组成的肿瘤微环境触发的人工脂质包膜来包裹复制缺陷型 Ad(dAd)或同时表达短发夹 RNA(shRNA)针对 Wnt5(shWnt5)和核心蛋白聚糖(dAd/LP-GE-PS 或 oAd/LP-GE-PS)的 oAd。体外研究表明,dAd/LP-GE-PS 以 pH 响应和 EGFR 特异性方式转导乳腺癌细胞,在 EGFR 阳性细胞系中 pH 为 6.0 时轻度酸性条件下,其转导水平高于裸 Ad。体内生物分布分析表明,与裸 oAd、无 PUSSM 或 EGFR 靶向肽部分的脂质体包封的 oAd(oAd/LP)或仅用 EGFR 靶向肽包封的 oAd(oAd/LP-GE)相比,全身性给予 oAd/LP-GE-PS 可导致肿瘤内病毒颗粒积累水平显著增加在过表达 EGFR 的 MDA-MB-468 乳腺癌异种移植模型中,这表明 pH 敏感性和 EGFR 靶向能力是 oAd 有效全身递送的重要组成部分。此外,与裸 oAd 相比,所有脂质体 oAd 制剂(oAd/LP、oAd/LP-GE 和 oAd/LP-GE-PS)的全身性给予均显著减少了病毒在肝脏中的积累。总之,我们的研究结果表明,pH 敏感和 EGFR 靶向的脂质体全身性递送 oAd 可能是一种很有前途的策略,可以解决 oAd 的传统局限性,以安全有效的方式治疗 EGFR 阳性癌症。